A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis

[1]  A. Ashworth,et al.  Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies , 2014, Oncogene.

[2]  M. Hidalgo,et al.  Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Sliwkowski,et al.  Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy , 2013, Clinical Cancer Research.

[4]  C. Obinger,et al.  Stability assessment on a library scale: a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc , 2013, Protein engineering, design & selection : PEDS.

[5]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[6]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[7]  K. Blackwell,et al.  Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells , 2012, Breast Cancer Research.

[8]  A. Scott,et al.  Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-MET , 2012, PloS one.

[9]  A. Plückthun,et al.  Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling* , 2011, The Journal of Biological Chemistry.

[10]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[11]  D. Burton,et al.  Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged , 2010, Journal of Virology.

[12]  D. Cunningham,et al.  Trastuzumab in gastric cancer. , 2010, European journal of cancer.

[13]  G. Himmler,et al.  Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. , 2010, Protein engineering, design & selection : PEDS.

[14]  C. Pyke,et al.  Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. , 2010, Cancer research.

[15]  Jonathan J. West,et al.  ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer , 2010, Clinical Cancer Research.

[16]  Y. Yarden,et al.  Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis , 2009, Proceedings of the National Academy of Sciences.

[17]  A. Jimeno,et al.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  G. Brockhoff,et al.  Flow Cytometric FRET Analysis of erbB Receptor Interaction on a Cell‐by‐Cell Basis , 2008, Annals of the New York Academy of Sciences.

[19]  Wannian Yang,et al.  Identification of the domain in ErbB2 that restricts ligand-induced degradation. , 2008, Cellular signalling.

[20]  K Dane Wittrup,et al.  Isolating and engineering human antibodies using yeast surface display , 2006, Nature Protocols.

[21]  W. R. Bishop,et al.  Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody , 2005, Molecular Cancer Therapeutics.

[22]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[23]  M. Sliwkowski,et al.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.

[24]  B. van Deurs,et al.  Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. , 2004, Molecular biology of the cell.

[25]  N. Neff,et al.  Purification of Her-2 extracellular domain and identification of its cleavage site. , 2003, Protein expression and purification.

[26]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[27]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[28]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[29]  W. Deen,et al.  Structural determinants of glomerular permeability. , 2001, American journal of physiology. Renal physiology.

[30]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[31]  Y. Yarden,et al.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.

[32]  Michele C. Kieke,et al.  Directed evolution of a stable scaffold for T-cell receptor engineering , 2000, Nature Biotechnology.

[33]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[34]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[36]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[37]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[38]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[39]  C. Macleod,et al.  Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Seliger,et al.  Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines , 2004, International journal of cancer.